New developments in treatments for spinal muscular atrophy (SMA) over the last few years have changed what is possible for people with SMA, allowing them to achieve new developmental milestones. However, these treatment ...
Dear SMA Community, While 2020 did not pan out as we had expected, Cure SMA remains extremely optimistic about the future for our community in 2021 and beyond. Here are the reasons why: ...
Dear SMA Community, As 2020 draws to a close, we want to provide an overview of our recent work in the community over the fourth quarter and updates related to clinical studies of ...
Below we have provided an update from Biogen regarding the status of its DEVOTE clinical trial. For more information about SPINRAZA (nusinersen), visit https://www.curesma.org/spinraza/. ++++++++++++++++++++ Biogen's DEVOTE study is designed to evaluate the ...
During our past fiscal year—from July 1, 2019 to June 30, 2020—Cure SMA funded more than $9 million in new and ongoing research and care initiatives. This money will be used strategically to ...
To the full spinal muscular atrophy (SMA) community, we want you to know that Cure SMA is continuing to support you with information and resources related to the COVID-19 pandemic. The following frequently ...
Dear SMA Community, Although this year has brought with it many challenges, the SMA community continues to demonstrate its strength and resilience. Cure SMA remains committed to bringing you the information, resources, and ...
Dear Members of the SMA Community, As we celebrate National Family Caregivers Month this November, Biogen acknowledges the vital role caregivers have in our society, including within our spinal muscular atrophy (SMA) community. ...
Cure SMA is excited to be announcing—along with support from Biogen—the launch of two new programs for adults with SMA. First, we will test your knowledge of random (and useless) facts with an ...
Contributors: Dr. Mary Schroth and Dr. Robert Graham Influenza (or flu) is a serious respiratory infection, and people of any age can get it. Since 2010, the Centers for Disease Control and Prevention ...
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced 6-month interim results from their clinical program for its ...
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting stories about adults with SMA in the workforce and are pleased to ...
